|
3rd
Annual
BIOTECHNOLOGY INDUSTRY CONFERENCE
May 15, 2003 ~ The
Harvard Club, NYC
27 West 44th Street, between
Fifth and Sixth Avenues
SPEAKERS Alan
Smith, CSO & SVP Research, Genzyme
Before he came to Genzyme in 1989, Dr. Smith held the position
of Vice President and Scientific Director at Integrated
Genetics. Prior to joining IG in 1984, Dr. Smith was head of
the Biochemistry Division of the National Institute for
Medical Research, Mill Hill, London, England. Previous to
that, he was a member of the scientific staff of the Imperial
Cancer Research Fund, London, England, and he began his career
as a recipient of the European Molecular Biology Traveling
Fellowship, Department of Molecular Biology, University of
Aarhus, Denmark. Dr. Smith has authored and co-authored over
180 publications in the areas of biochemistry, virology, and
molecular biology. In addition, he has served on various
committees, including the MRC Cells board, London, England;
EMBO Course and Workshop, Heidelberg, Germany; Board of
Studies in Biochemistry, London University, London, England;
MRC Cells Board Grants Committee A, London, England; and the
Nucleotide Group Committee of the Biochemical Society, London,
England. Peter
Feinstein, General Partner, BioVentures Investors
Mr. Feinstein co-founded BioVentures Investors in 1997
and has been a General Partner of Fund I since its inception.
In 1987 he founded Feinstein Kean Partners Inc., now known as
Feinstein Kean Healthcare ("FKH"), in Cambridge,
Massachusetts. FKH is a leading biotechnology communications
and strategic consulting firm. Together with its subsidiary,
Kendall Strategies, FKH provides business development and
strategic planning, investor relations, scientific
communications, and product marketing services to
biotechnology companies. In 1999, Mr. Feinstein and his
partners sold the business to an affiliate of WPP Group, the
world’s largest communications and advertising company. Mr.
Feinstein has been an advisor in numerous life science company
IPOs, private placements, limited partnerships, corporate
repositionings, mergers, and start-ups. Mr. Feinstein
pioneered the approach of establishing valuation prior to
product sales through scientific and business achievements and
is experienced in establishing biotechnology valuation and
financing. In 1982 Mr. Feinstein was hired by Dr. Gilbert to
serve as Vice President, Corporate Communications at Biogen
N.V. From 1982 to 1987, his responsibilities at Biogen
included investor relations and press relations programs in
Europe and in the U.S., and all other corporate communications
activities for this leading international biotechnology
company. Earlier, from 1980 to 1982, Mr. Feinstein was Vice
President at Newsome & Co., Inc., New England’s largest
public relations agency, where he created and implemented
corporate communications projects and programs for clients
including Biogen, General Electric, IBM, Raytheon, and Coopers
& Lybrand. Mr. Feinstein was a co-founder and served as a
Director of the Massachusetts Biotechnology Council from its
inception in 1985 until 1997. He was a member of the
Governor’s Task Force, Subcommittee on Biotechnology and
Pharmaceutical Development, and has produced numerous industry
surveys and reports. Mr.Feinstein earned his B.A. from
New York University in 1969. Michael
Lytton - Partner, Oxford Bioscience Partners
Michael Lytton joined Oxford Bioscience Partners in 2001.
Prior to that, he was Partner, Chairman of the Technology
Group and a member of the Executive Committee of Palmer &
Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the
Boards of Directors of Acambis plc, ActivX Biosciences Inc.,
Descartes Therapeutics, Inc., GPC Biotech AG, Graffinity
Pharmaceutical Design GmbH, Psychiatric Genomics Inc. and
Rib-X Pharmaceuticals. Mr. Lytton is also a member of the
Research and Technology Development Committees of the Beth
Israel Deaconess Medical Center (an affiliated Harvard
teaching hospital) and the Center for Blood Research, Harvard
Medical School, where he is also a member of the Board of
Overseers. In addition, he serves on the Advisory Committee to
Connecticut Innovations, a public agency funding early-stage
biomedical companies in Connecticut. Mr. Lytton writes a
column on issues facing early-stage biomedical companies for
Start-Up magazine, published by Windhover Information. Mr.
Lytton has served on the Executive Board of the MIT Enterprise
Forum and the Patent Committee of the Boston University
Medical Center. Mr. Lytton was a summa cum laude graduate of
Princeton University and a recipient of a Fulbright
Scholarship for study at the University of London. Mr. Lytton
received a J.D. degree cum laude from Harvard Law School. Mr.
Lytton also received a M.Sc. degree in Epidemiology and
Medical Statistics from the London School of Hygiene and
Tropical Medicine. Andrew
Meadow - General Partner, HealthCon Corp
Mr. Meadow concentrated the last fourteen years in
a variety of senior management roles the focus of which was to
craft opportunities, define appropriate strategies, valuing
the financial implications underpinning what products can and
should be launched, and creating decisive analytical and
quantitative approaches that help monetize business plans and
launch cutting edge technologies and therapies. In conjunction
with his financial due diligence and corporate valuation
efforts, Mr. Meadow has been an advocate of using innovative
quantitative methods to ascertain the risk profile of a
transaction, including how real option and probability
analysis can assist management in mitigating the risk
associated with some transactions. Prior to HealthCon, Mr.
Meadow worked for Essex Woodlands Health Care Ventures in
evaluating private equity/venture technology opportunities
within the health care services, diagnostics, and device
arenas. Prior to
this experience, Mr. Meadow served as the Manager for Baxter
International’s Corporate Business Development Team. At
Baxter, he evaluated multiple biotechnology ventures as well
as emerging treatments and products for joint venture,
acquisition, technology transfer, new product development and
licensing opportunities within the Oncology, tissue
engineering, cell and gene therapy, and BioScience arenas.
Before Baxter, Mr. Meadow served on UBS Warburg’s Global
Healthcare Investment Banking Team where he worked on a
significant number of M&A, high-yield debt, private
placement, follow-on, and IPO transactions within the health
care industry.
Mr. Meadow completed his MBA in Health Care Finance and
Strategy from Case Western Reserve University’s Weatherhead
School of Management where he was a recipient of the
Weatherhead Merit Scholarship.
In addition, Mr. Meadow has completed Advance Masters
Degree studies in Health Care and International Economics at
the Rotterdam School of Management’s Erasmus University.
Before embarking upon his career, Mr. Meadow graduated
with Honors and Academic Distinction from Franklin and
Marshall College, where he was a four year varsity letterman
in three different sports.
Prior to completing his MBA, Mr. Meadow worked for nine years
in Central and Eastern Europe in a variety of executive level
positions in the areas of product development, corporate
restructuring, treasury, and financial control. During his
tenure in Europe, Mr. Meadow gained extensive operational
experience in managing early stage health and consumer goods
concerns throughout Central and Eastern Europe.
Mr. Meadow is fluent in two languages including Polish
and Russian.
Owen
Garrick, MD MBA - Executive Director
& Global Head of M&A Negotiations, Novartis
Dr. Garrick is responsible for structuring, negotiating and
closing both M&A and strategic investment deals that are
beyond the scope of licensing-in structures.
He specifically oversees small and medium size company
acquisitions, hybrid equity/license right deals, mature
product divestments, and venture investments in biotechnology
companies.
Dr.
Garrick comes to Novartis from Helix Health Partners where he
was a Principal focused on building start-up companies in the
biopharmaceutical, medical device, and life science technology
industries. He was actively involved in intellectual property validation,
revenue growth strategies, and fund raising.
Previously he spent four years at Goldman Sachs in New
York. He was an
investment advisor working with private healthcare companies
as they looked to grow, raise capital, and perform initial
public offerings. Dr.
Garrick earned his MD from the Yale School of Medicine and MBA
from Wharton Business School.
He holds and AB in Psychology from Princeton and
continues to be an active alumnus, serving on the national
fundraising board.
Dr.
Garrick also serves on several boards and professional
committees, including the New York Blood Center, the American
Medical Association's Minority Affairs Consortium, and the
American College of Healthcare Executive's Research &
Development Committee.
Kevin
Noonan - Partner, McDonnell Boehnen Hulbert & Berghoff
Mr. Noonan has extensive experience in
biotechnology and the chemical arts. A registered patent
agent since 1991, Dr. Noonan brings over 10 years' experience
as a molecular biologist working on high-technology problems
to his legal work. Dr. Noonan has wide experience in all
aspects of patent prosecution and client counseling on
validity, infringement, and patenting strategy matters.
He represents pharmaceutical and biotechnology companies both
large and small, and he is particularly experienced in
representing university clients in both patent prosecution and
licensing to outside investors. Dr. Noonan received a PhD in
molecular biology from Princeton University, where his thesis
work involved genetic analysis of oncogenesis in mammalian
cells. Dr. Noonan was also a postdoctoral fellow
supported by the National Cancer Institute at the University
of Illinois at Chicago, where he studied multidrug resistance
in mammalian tumor cells. During his fellowship Dr.
Noonan developed a variety of novel methods based on the
polymerase chain reaction, including quantitative analysis of
mammalian gene expression. Dr. Noonan is the author of
several articles and has lectured extensively on his
scientific work. Dr. Noonan graduated, cum laude, from
the John Marshall Law School. He is admitted to practice
in Illinois and Massachusetts and is currently an adjunct
professor of law at the De Paul University Law School, where
he teaches biotechnology patent law. Dr.
Lester Crawford - Deputy Commissioner, FDA
As the Deputy Commissioner for the Food and Drug
Administration, Dr. Crawford has extensive experience in FDA
matters. His previous government experience included serving
as head of the FDA's Center of Veterinary Medicine and, from
1987 to 1991, as administrator of the Department of
Agriculture's Food Safety and Inspection Service. From 1993 to
1997, Crawford was the executive director of the Association
of American Veterinary Medical Colleges. During ten years at
the Food and Drug Administration and U.S. Department of
Agriculture, he played major roles in mandatory nutrition
labeling, the General Agreement on Tariffs and Trade (GATT),
and the control of chemicals and microorganisms in the food
supply. Most recently Dr. Crawford served as the Director of
the Virginia Tech Center for Food and Nutrition Policy. Dr.
Crawford has also served as Executive Vice-President of the
National Food Processors Association, and Chairman, Department
of Physiology-Pharmacology, University of Georgia. Dr.
Crawford has a doctorate in veterinary medicine from Auburn
University and he also earned the Ph.D. degree in pharmacology
from the University of Georgia. He is a Fellow of the Royal
Society of Medicine (UK), and also a Fellow of the
International Society of Food Science and Technology.
Dr. Kenneth Carter -
President & CEO, Avalon Pharmaceuticals
Dr. Carter has an extensive background in both cytological
(chromosomes) and molecular (genes) genetics, including
database mining and gene-array design and analysis. His
scientific work is widely referenced and has been featured on
the cover of several journals, including Science, the world's
foremost scientific periodical. He received his Ph.D. in Human
Genetics and Cell Biology from the University of Texas Medical
Branch at Galveston in 1989, and was honored with the
University's distinguished alumnus award in 1999. Dr. Carter
also completed four years of postdoctoral research at the
University of Massachusetts while receiving research
fellowships from the Human Genome Center (NIH) and the
Muscular Dystrophy Foundation. In 1993 Dr. Carter became one
of the first scientists at Human Genome Sciences (HGSI), where
he developed and directed the company's gene mapping
initiative. In this capacity he has played a direct role in
the discovery, cloning, and chromosomal mapping of dozens of
new human genes. Among these were several disease genes
including a family of genes involved in colon cancer, whose
elucidation was named the 1994 "Discovery of the
Year" by Science. In 1998 Dr. Carter became President of
International Genetics Associates, Inc. (IGA), a platform
technology company developing cutting-edge molecular
cytogenetic technology. He left IGA in December 1999, to
become CEO, President & Co-Founder of Avalon
Pharmaceuticals.
Dr. Jennie Mather -
Founder, President & CEO, Raven Biotechnologies
Dr.
Mather has thirty years of experience in cell culture and cell
biology research. She obtained her PhD from the University of
California, San Diego in 1975. While working as an NIH
postdoctoral fellow in the laboratory of Dr. Gordon Sato, she
was one of the first to show that serum could be replaced by a
mixture of known hormones, growth factors and attachment
factors to grow established cell lines. She also developed
"F12/DME" medium, now widely used in serum-free
culture. After a year as an NIH/INSERM Exchange Scientist at
the Hopital Debrousse INSERM U 162 in Lyon, France, Dr. Mather
joined the faculty of The Rockefeller University and the
Population Council. While there, she established a number of
normal cell lines from endocrine tissues. In 1984 she joined
Genentech, Inc. as a Senior Scientist and was promoted to
Staff Scientist in 1988. She was involved in genetically
engineering the production parent line, and designing cell
culture production processes for 3 currently marketed
recombinant protein products. In 1994 she and her group moved
to the Research division of Genentech where she initiated
discovery research projects in the areas of neurobiology,
endocrinology, and cancer biology and contributed to a
genomics screening effort. Dr. Mather was a member of more
than 12 project teams, and was the project team leader of the
activin/ inhibin project at Genentech. This has given her
exposure to most aspects of biotechnology product development,
from the initial assessment of ideas, to forming and leading a
team through the research, and early development phases of a
new drug. Dr Mather is a co-inventor on more than 20 patents
and has authored or edited several books and more than 150
journal articles and book chapters. In Jan 1999 Dr. Mather
left Genentech to found Raven biotechnologies, which is
specializing in using cell biology as the key to the rapid
discovery and utilization of relevant cells, proteins, and
small molecules to treat unmet medical needs. Gail
Maderis - President, Genzyme Molecular Oncology
With more than 15 years of management experience in
biotechnology and healthcare environments, Ms. Maderis
possesses a diverse portfolio of knowledge and skills in
business management, research and development, and gene
therapy. In 1997, Ms. Maderis conceived and created Genzyme
Molecular Oncology, one of Genzyme Corporation's three
tracking stock divisions, which focuses on the development and
commercialization of innovative therapeutics to treat cancer.
Prior to joining Genzyme, Ms. Maderis spent seven years as a
manager at Bain & Company, where she was responsible for
developing and implementing major strategic programs for
several large companies in the pharmaceutical and healthcare
industries. She earned a Bachelor's degree with honors in
Business Administration from the University of California,
Berkeley and received an MBA from Harvard Business School. Mark
Leuchtenberger - President & CEO, Therion Biologics
Mark Leuchtenberger joined Therion as President
and CEO from Biogen, where he served as Vice President,
International. In this capacity, he led all commercial
operations outside of North America. Mark joined Biogen in
1990 as Product Manager and served as Program Executive for
Amevive™, until assuming Avonex® program leadership in
1993. In this role, Mark was responsible for managing the
late-stage development, registration, marketing and North
American launch of Avonex®. During his tenure at Biogen, he
held several senior positions, including Vice President of
Sales, Marketing and Business Development where he oversaw the
company's global market, licensing and strategic partnership
activities. Prior to Biogen, he worked as a Senior Consultant
at Bain and Company and specialized in healthcare products and
services. Mark received a M.B.A. from the Yale School of
Management and a B.A. from Wake Forest University. Kevin DeGeeter -
Editor, FierceBiotech
Kevin
DeGeeter has spent his career at the intersection
biotechnology and finance. As the Editor of FierceBiotech, he
produces a free daily email newsletter read by more
than 20,000 biotechnology and pharmaceutical industry
executives. Prior to
joining FierceBiotech, Kevin was Senior Healthcare Writer for
The Daily Deal, a daily newspaper targeting investment bankers
and venture capitalists. His stories have been syndicated on
CNBC.com, BioSpace.com and other financial websites. During
the late 1990s he conducted equity research for Wall Street
firms such as J.P. Morgan and PaineWebber. He is a graduate of
Colgate University with a degree in economics and currently
lives in New York.
In
addition to his work with FierceBiotech, he regularly writes
profiles of biotechnology and private equity executives for
various print publications.
Stanley
Erck, President & CEO, Iomai Corporation
Mr. Erck applies his 25 years of management experience in the
healthcare and biotechnology industry (Baxter International,
Procept and Integrated Genetics) to shepherd the development
and commercialization of Iomai technology. In addition to
successfully negotiating major alliances with pharmaceutical
and biotechnology companies and bringing products into
clinical trials, as CEO he has managed the process of
developing companies from private funding through an IPO,
raising over $100 million. Mr. Erck received his B.S. from the
University of Illinois and an M.B.A. from the University of
Chicago. E.
Kurt
Kim - Founder, President & CEO, Private Raise LLC
Mr. Kim has spent the past decade in various advisory and
deal-making
capacities within the financial services sectors. Prior to
founding PrivateRaise, L.L.C., Mr. Kim was an Investment
Manager with Promethean Asset Management, L.L.C. and was
responsible for the origination, structuring, negotiations and
execution of investment opportunities involving Equity Private
Placements. Mr. Kim has had
significant experience in investing in Equity Private
Placements by Issuers
across a diverse range of industries/sectors and utilizing a
broad array of
investment structures. Prior to joining Promethean, Mr. Kim
worked as a management consultant for Mercer Management
Consulting and Towers Perrin, both based in New York, and has
had significant experience consulting with the senior
management of
financial institutions and intermediaries, including major
U.S. banks,
mutual funds, insurance companies and health care entities on
a variety of
strategic, economic/financial and organizational issues. Mr.
Kim holds an M.B.A. from the Wharton School of the University
of Pennsylvania and a B.A. in Economics and Government from
Wesleyan University. Mr. Kim has been quoted in leading
business newspapers and journals, including the Wall Street
Journal, Dow Jones Newswires, Inc. Magazine and Institutional
Investor. Mr. Kim is currently working on a PIPEs reference
book (as Co-Editor and contributing author) to be published by
Bloomberg Press in August 2003 titled: "PIPEs: A Guide to
Private Investments in Public Equity".
* PrivateRaise.com selected as Forbes 2002 `Best of the Web'
Pick *
PrivateRaise.com(TM) is one of only four market information
providers (along
with Thomson Financial, Bloomberg.com and BigDough.com)
honored as 'Best of
the Web' in the Financial Content Provider category.
Dr. Chris Mirabelli,
General Partner, HealthCare Ventures, LLC
Dr. Mirabelli has more than twenty years of experience in the
pharmaceutical and bio-
technology industry, and in biomedical research as both a
senior executive and scientist.
Dr. Mirabelli served as Chairman of the Board and Chief
Executive Officer of LeukoSite, Inc. from 1993 through 1999.
Under his leadership, LeukoSite became a premier
company in the discovery and development of therapeutics
targeting white blood cell-
mediated diseases. The company raised more than $125MM in
capital in private, corporate and public financings,
established corporate R&D alliances with major
pharmaceutical companies, and through internal R&D and the
acquisition of technology
and other companies, constructed a pipeline of multiple
product opportunities spanning
late phase clinical development and early research and drug
discovery. LeukoSite's success culminated in its merger with
Millennium Pharmaceuticals in December, 1999. Dr. Mirabelli
presided over the integration of LeukoSite into Millennium as
President of Pharmaceutical R&D and a member of the
company's Board of Directors until mid-2000. Under Dr.
Mirabelli's direction, LeukoSite grew from a valuation of
$16MM at inception to near $1 billion upon completion of the
merger. Dr. Mirabelli was a founder of Isis Pharmaceuticals,
Inc., where he served as an executive vice president from 1992
to 1993, senior vice president of research and preclinical
development from 1991 to 1992, and vice president of research
from 1989 to 1991. He was a member of SmithKline and French
Laboratories R&D Division from 1981 to 1988, where he held
a number of positions including director of the Molecular
Pharmacology Department. Dr. Mirabelli received his Ph.D.
degree in molecular pharmacology from Baylor College of
Medicine in Houston, Texas in 1981. He has authored more than
191 scientific publications, abstracts and review articles,
and is an author on 18 issued patents. He joined HCV in 2000.
Thomas
Konatich - CFO/Acting CEO, SIGA Technologies
Mr. Konatich has served as Vice President and
Chief Financial Officer since 1998. He also currently
serves as Secretary and Treasurer. Before joining SIGA,
Mr. Konatich served as Chief Financial Officer and a Director
of Innapharma, Inc., a privately-held pharmaceutical
development company. Prior to that, Mr. Konatich served
as Vice President and Chief Financial Officer of Seragen,
Inc., a publicly traded biopharmaceutical development company.
For five years before that, he was Treasurer of Ohmicron
Corporation, a venture capital firm. Mr. Konatich has an
M.B.A. from the Columbia Graduate School of Business and B.B.A.
from St. John's University. Dr.
Srinivas Akkaraju - Principal, JP Morgan Partners
Srinivas joined the Life
Sciences team in the Healthcare Group at JPMorgan Partners,
LLC in April '01. From October '98 to April '01, Srinivas was
in Business and Corporate Development at Genentech, Inc., most
recently as Senior Manager. There he was responsible for
worldwide partnering activities including technology access
deals, in-licensing of early and late-stage therapeutics, and
out-licensing of Genentech development projects. In addition
to his business development role, Srinivas also served for the
last year as Project Team Leader for one of Genentech's
clinical development products. During this time, Srinivas was
also a founding member of BioStreet, an online marketplace for
biotech opportunities. Prior to joining Genentech in 1998,
Srinivas was a graduate student at Stanford University, where
he earned his M.D. and Ph.D. in Immunology. Srinivas earned
his undergraduate degrees in Biochemistry and Computer Science
from Rice University in 1990. He is currently a Director of
Eyetech Pharmaceuticals. Dr.
Ginger Johnson - Senior Consultant, Defined Health
Dr. Johnson brings an array of valuable experience and
expertise to Panacea. With a career that includes positions in
basic and applied scientific research, private equity
investing, and corporate development, Dr. Johnson has a unique
understanding of the issues critical to the success of a
growing biotechnology venture and the proven ability to
identify the commercial viability of emerging technologies and
trends in the life science industry. Currently, Dr. Johnson is
a Special Consultant at Defined Health, Inc., a leading
business development strategy consulting firm for the
pharmaceutical, biotech, and healthcare industries. She
participates in and manages core assessment and strategic
consulting projects, with a special emphasis on CNS-associated
therapeutic categories. Dr. Johnson was Vice-President for
Corporate Development team at Skila, Inc. where she identifies
and executes strategic partnerships and works in conjunction
with Skila's executive team to define their corporate
strategy. Skila, Inc. is a next-generation Internet company
dedicated to providing global business intelligence and
eKnowledge solutions for the pharmaceutical, medical device,
and biotechnology industries. Dr. Johnson joined Skila from
Chase Capital Partners (now JP Morgan Partners), a global
private equity investment firm with approximately $7.0 billion
under management, where she was the Director of Life Science
Research. While at CCP, Dr. Johnson's research and investment
activities focused on the pharmaceutical, biotechnology,
medical device, and eHealth industries. Prior to CCP, Dr.
Johnson was the Associate Director of the Center for
Biotechnology at Northwestern University where she helped to
develop an innovative graduate program that combines the
science and business of biotechnology. Dr. Johnson spent eight
years in basic and applied research, primarily in the field of
Alzheimer's disease, at the National Institutes of
Health/National Institute of Mental Health and an emerging
biotechnology company. She has published 14 peer-reviewed
publications, presented over 20 abstracts, and is an inventor
on several patents. Dr. Johnson received a B.S. in Molecular
biology from the University of Tennessee, a Ph.D. in Genetics
from George Washington University, and has completed graduate
studies at the J.L. Kellogg Graduate School of Management at
Northwestern University. Dr.
Joseph Jasinski - Worldwide Operations Manager, IBM Life
Sciences
Prior to his current position,
he was the Senior Manager of
the Computational Biology Center at
IBM Research. In that role he oversaw IBM’s
basic research efforts at the
interface between information technology
and biology. He has also managed and carried
out research in nanotechnology, materials
chemistry and chemical kinetics in his 20 year career
with IBM. Dr. Jasinski graduated from
Dartmouth College in 1976 with an A.B. in
mathematics and chemistry. He received a Ph.D. in
chemistry from Stanford University in 1980.
Following post-doctoral work at the University of
California, Berkeley, he joined the IBM Thomas J. Watson
Research Center as a Research Staff Member in 1982. He
is a Fellow of the American
Physical Society and the American
Association for the Advancement of Science. He has
authored or co-authored over 50 scientific papers and holds
two patents.
Eileen
Smith Ewing, Esq. - Partner & Chair Life Sciences Group,
Kirkpatrick & Lockhart
Ms. Ewing is a partner in the national law firm of Kirkpatrick
& Lockhart LLP, resident in its Boston office.
She represents her pharmaceutical and biotechnology
clients in complex transactions including intellectual
property licensing and technology transfers, domestic and
transnational mergers, acquisitions, joint ventures, and other
strategic corporate alliances.
Ms. Ewing serves as chair of Kirkpatrick &
Lockhart’s firmwide Life Sciences practice group. Ms. Ewing
has a particular interest in Pacific Rim legal transactions.
She was graduated from Harvard University (where she
was a Radcliffe National Scholar) with a bachelor’s degree
in East Asian Studies summa cum laude.
She received the JD degree from Columbia University Law
School, as well as graduate degrees in Japanese Intellectual
History from Columbia. Ms.
Ewing writes and speaks frequently on business and legal
topics of interest to the life sciences industries. She is authoring the 2003 edition of ALI-ABA’s text, Negotiating
and Documenting Mergers and Acquisitions.
She also is serving as the General Editor of
American Lawyer Media’s treatise, currently in preparation,
on biotechnology licensing deals. Bill
Tanner - Managing Director, Head of Biotechnology, Leerink
Swann
Mr. Tanner joined Leerink Swann & Company in
2002 as a research analyst and the Head of the Biotechnology
group. Dr. Tanner joins the firm with six years' experience in
biotech equity research, most recently at SG Cowen Securities
Corp., where he served as Managing Director and Biotechnology
Analyst. Before joining SG Cowen, he served as Biotechnology
Analyst at the former Vector Securities International and at
Principal Financial Securities. Prior to his positions in
equity research, Dr. Tanner was a Research Associate at
Washington University School of Medicine's Center for
Immunology and Department of Pathology. Dr. Tanner received
his MBA from the Olin School of Business at Washington
University and his Ph.D. in Physiology from Texas A&M
University. Dr. Tanner did his post-doctorate work at Monsanto
Co. in the department of Molecular Genetics and Mammalian
Biology. He was a recipient of the National Research Service
Award from the National Institutes of Health and received a
postdoctoral fellowship at the Juvenile Diabetes Foundation.
Josh
Wolfe - Co-Founder & Managing Partner, Lux Capital
Josh Wolfe is a co-founder and Managing Partner of
Lux Capital focusing on investments in Nanotechnology and
Software. Before forming Lux Capital, he worked in Salomon
Smith Barney's Investment Banking group, where his experience
included a $4 billion hotel merger, and a defense against an
unsolicited LBO. Josh has also worked in capital markets while
at Merrill Lynch on its Financial Futures &
Options/Government Strategy desk and at Prudential Securities
in its Municipal Finance department. Prior to venturing into
the financial world, Josh conducted and published cutting edge
AIDS/immunopathology research in Cell Vision and The Journal
of Leukocyte Biology, leading medical/immunology journals.
Josh graduated with distinction from Cornell University with a
B.S. in Economics and Finance. He has been an invited guest
speaker, lecturer and panelist on nanotechnology to Harvard,
Yale, Wharton, Columbia, Cornell, Merrill Lynch, Capitol Hill,
government labs, and officials in France, Canada, UK, Spain
and Germany. Josh is a a co-founder of The NanoBusiness
Alliance, a Senior Associate of the Foresight Institute for
Nanotechnology, the Coordinator for the Institute of Molecular
Manufacturing's Prize in Computational Nanotechnology, and a
member of the Cognitive Science Society. Josh is author of the
acclaimed "Nanotech Report" and Editor of Forbes'
new publication, the "Forbes/Wolfe Nanotech Report."
Vijaya
Vasista - COO,
Nanosphere
Ms. Vasista has more than 17 years
experience in the medical device, medical hardware and
clinical diagnostics markets. Before joining Nanosphere in
November of 2000, Ms. Vasista was Vice President, Global
Marketing at Baxter International, where she provided
strategic global marketing direction at their Fenwal division
and achieved $500M in sales. At Baxter International, Ms.
Vasista held senior management positions in several divisions
where she drove global business development initiatives,
created and managed high caliber, multifunctional teams, and
established collaborative regional and global relationships
essential to product development and marketing. Ms. Vasista
received her M.B.A. from the University of Chicago and was a
visiting student at the London School of Economics. She holds
a B.S. in economics from the University of Pennsylvania,
Wharton School.
Dr.
Vladimir Makarov - Co-Founder & CSO, Rubicon Genomics
Dr. Makarov is a
co-founder of Rubicon Genomics and Chief Scientific Officer.
Dr. Makarov is co-inventor of the core technology of Rubicon
Genomics and is currently leading the R&D team at Rubicon.
Dr. Makarov has held research positions at the Engelhardt
Institute of Molecular Biology at the USSR Academy of Science,
and most recently at the Biophysics Research Division at the
University of Michigan. Dr. Makarov is a scientist with broad
expertise in different fields including solid state physics
and optics, biophysics of DNA and DNA-protein complexes,
chromatin structure, and DNA and protein enzymology. His
recent contributions to genomics include new DNA sequencing
and amplification techniques. He is an inventor on 5
University of Michigan patent applications and has over 50
scientific publications. Dr. Makarov has a Ph.D. in Physics
and Mathematics from Leningrad State University.
Dr.
Juan Sanchez - Research Associate, Punk Ziegel
Dr. Sanchez is an Associate of the equity research team at
Punk, Ziegel & Company, covering the biotechnology and
nanotechnology sectors. He has more than five years of
experience in clinical medical practice. He has a background
in the pharmaceutical industry as well as in science and
technology assessment at Columbia University. He holds an MIA
degree from Columbia University, an MBA from the University of
Los Andes and an MD from Javeriana University.
Salvatore
Salamone - Senior IT Editor, Bio IT World
Salvatore Salamone
is the Senior IT Editor at Bio-IT World, IDG’s monthly
magazine that covers technology for the life sciences. He is
responsible for providing IT coverage for the magazine and the
publication’s Web site. Additionally, he publishes a
bi-weekly e-newletter for Bio-IT World called Networking Under
the Microscope, which looks at major networking technology
trends and issues as they apply to the life sciences. Mr.
Salamone is a frequent speaker at industry conferences and has
helped organize and conduct industry roundtable discussions on
a variety of topics. He is author of three books including
“The Complete Guide to VPNs” (InternetWeek, 1999);
“Managing Remote Connectivity” (McGraw-Hill/Osborne, 1997;
Spanish edition published July 1998; Chinese edition published
September 1998) and co-author of “Reducing the Cost of LAN
Ownership” (Van Nostrand Reinhold, 1995). Mr. Salamone has
served as an editor at most of the major industry trade
publications including InternetWeek, Data Communications, LAN
Times, Byte Magazine, and Network World. While at InternetWeek,
Mr. Salamone established the InternetWeek VPN Alliance, an
educational group whose purpose is to be a resource for IT
managers interested in virtual private networking. In this
role, he developed and presented 3/4 of a day seminars on the
business and technical issues of using VPNs, and wrote four
VPN White Papers published in InternetWeek.
He holds a B.S. and M.S., both in physics, from Boston
College.
REGISTER
FOR THIS EVENT
|
